TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05130437: A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Sponsor: ModernaTX, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$338,640

Rescue Site Savings

+$225,760

Unlock Full NCT05130437 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05130437 Rescue Dossier →